Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis

Background: Adjuvant sorafenib may enhance the efficacy of transarterial radioembolization with yttrium-90 in hepatocellular carcinoma patients. The aim of this study is to assess the efficacy and safety of radioembolization plus sorafenib in comparison to radioembolization alone. Methods: Out of 17...

Full description

Bibliographic Details
Main Authors: Antonio Facciorusso, Irene Bargellini, Marina Cela, Ivan Cincione, Rodolfo Sacco
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
HCC
Online Access:https://www.mdpi.com/2072-6694/12/4/897